Hypertension and hypokalemia: Unusual syndromes

Connecticut Medicine

Volumn 61, Issue 2, 1997, Pages 67-75

  Cruz, Dinna N ^a   Perazella, Mark A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; DEXAMETHASONE; HYDROCHLOROTHIAZIDE; MINERALOCORTICOID; SPIRONOLACTONE; TRIAMTERENE;

HUMAN; HYPERALDOSTERONISM; HYPERTENSION; HYPOKALEMIA; LIDDLE SYNDROME; REVIEW;

ANIMALS; HUMANS; HYPERTENSION; HYPOKALEMIA; MINERALOCORTICOIDS; SYNDROME;

EID: 0030904103     PISSN: 00106178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Smith JD, Perazella MA, DeFronzo RA: Hypokalemia, in Arieff AI, DeFronzo RA (eds): Fluid, Electrolyte, and Acid-Base Disorders, chap 9. New York: Churchill Livingston, 1995; 387-426.
2. Shackleton CHL, Honour JW, Dillon MJ, et al: Hypertension in a 4-year old child: Gas chromatographic and mass spectrometric evidence for deficient hepatic metabolism of steroids. J Clin Endocrinol Metab 1980; 50:786-92.
3. Shackleton CHL, Rodriguez J, Arteaga E, et al: Congenital 11β-hydroxysteroid dehydrogenase deficiency associated with juvenile hypertension; Corticosteroid metabolite profiles of four patients and their families. J Clin Endocrinol Metab 1985; 22:701-12.
4. New MI, Levine LS, Biglieri EG, et al: Evidence for an unidentified steroid in a child with apparent mineralocorticoid hypertension. J Clin Endocrinol Metab 1977; 44:924-33.
5. Ulick S, Levine LS, Gunczler P, et al: A syndrome of apparent mineralocorticoid excess associated with defects in the peripheral metabolism of cortisol. J Clin Endocrinol Metab 1979; 49:757-64.
6. Edwards CRW, Stewart PM, Nairn IM, et al: Cushing's disease of the kidney. J Endocrinol 1985; 104S:53.
7. Lakshmi V, Monder C: Evidence for independent 11-oxidase and 11-reductase activities of 11-reductase activites of 11β-hydroxysteroid dehydrogenase: Enzyme latency, phase transitions and lipid requirements. Endocrinology 1985; 116:552-60.
8. Mune T, Rogerson FM, Nukkila, et al: Human hypertension caused by mutations in the kidney isoenzyme of 11β-hydroxysteroid dehydrogenase. Nat Genet 1995; 10:394-9.
9. Stewart PM, Krozowski ZS, Gupt A, et al: Hypertension in the syndrome of apparent mineralocorticoid excess due to mutation of 11β-hydroxysteroid dehydrogenase type 2 gene. Lancet 1996; 347:88-91.
10. Ulick S, Chan CK, Kide NR, et al: A new form of the syndrome of apparent mineralocorticoid excess. J Steroid Biochem 1989; 32:209-12.
11. Shackleton CHL, Stewart PM: The hypertension of apparent mineralocorticoid excess (AME) syndrome, in Biglieri EG, Melby JC (eds): Endocrine Hypertension. New York: Raven Press Ltd, 1990:155-73.
12. Revers FE: De behandeling van ulcus ventriculi en ulcus duodeni met succus liquiritae. Ned T Geneesk 1948; 92:2968-73.
13. Blachley JD, Knochel JP: Tobacco chewer's hypokalemia: Licorice revisited. N Engl J Med 1980; 302:784-5.
14. Girerd RJ, Rassaert CL, DiPasquale G: Endocrine involvement in liquorice hypertension. Am J Physiology 1960; 198:718-20.
15. Borst JGG, Ten Holt SP, De Vries LA, Molhuysen JA: Synergistic action of liquorice and cortisone in Addison's and Simmond's disease. Lancet 1953; 1:657-63.
16. Armanini D, Karbowiak I, Funder JW: Affinity of liquorice derivatives mineralocorticoid and glucocorticoid receptors. Clin Endocrinol 1983; 19:609-12.
17. Hoefnagels WHL, Kloppenberg PWL: Antimineralocorticoid effects of dexamethasone in subjects treated with glycyrrhetinic acid. J Hypertension 1983; 1(suppl 2):313-5.
18. Salassa RM, Mattox VR, Rosevear JW: Inhibition of the mineralocorticoid activity of liquorice by spironolactone. J Clin Endocrinol 1962; 22:1156-9.
19. Stewart PM, Wallace AM, Valentino R, et al: Mineralocorticoid activity of liquorice: 11-beta-hydroxysteroid dehydrogenase deficiency comes of age. Lancet 1987; 2:821-3.
20. Valentino R, Stewart PM, Burt D, et al: Licorice inhibits 11-beta-hydroxysteroid dehydrogenase in the rat. J Endocrinol 1987; 112S:260.
21. Whorwood CB, Sheppard MC, Stewart PM: Licorice inhibits 11-beta-hydroxysteroid dehydrogenase messenger ribonucleic acid levels and potentiates glucocorticoid hormone action. Endocrinology 1993; 132:2287-92.
22. Conn JW, Rovner DR, Cohen E: Liquorice-induced pseudoaldosteronism. JAMA 1968; 205:80-4.
23. Farese VR, Biglieri EG, Shackleton CH: Licorice-induced hypermineralocorticoidism. N Engl J Med 1991; 325:1223-7.
24. Edwards CRW: Lessons from licorice. N Engl J Med 1991; 325: 1242-3.
25. Epstein MT, Aspiner EA, Donald RA et al: Liquorice toxicity and the renin-angiotensin-aldosterone axis in man. Br Med J 1977; 1:209-10.
26. Botero-Velez M, Cutis JJ, Warnock DG: Brief report: Liddle's syndrome revisited - a disorder of sodium reabsorption in the distal tubule. N Engl J Med 1994; 330:178-81.
27. Warnock DG, Bubien JK: Liddle syndrome: Clinical and cellular abnormalities. Hosp Prac 1994; 29:95-8, 104-5.
28. Liddle GW, Bledsoe T, Coppage WS: A familial renal disorder simulating primary aldosteronism but with negligible aldosterone secretion. Trans Assoc Am Physicians 1963; 76:199-213.
29. Canessa CM, Horisberger JD, Rossier BC: Epithelial sodium channel related to proteins involved in neurodegeneration. Nature 1993; 361:467-70.
30. Canessa C, Schild L, Buell G, et al: Amiloride-sensitive epithelial sensitive Na+ channel is made of 3 homologous subunits. Nature 1994; 367:463-7.
31. Shimkets RA, Warnock DG, Bositis CM, et al: Liddle's syndrome: Heritable human hypertension caused by mutations in the β subunit of the epithelial sodium channel. Cell 1994; 79:407-14.
32. Schild I, Canessa CM, Shimkets RA et al: A mutation in the epithelial sodium channel causing Liddle disease increases sodium channel activity in the Xenopus laevis oocyte expression system. Proc Natl Acad Sci USA 1995; 92:5699-703.
33. Snyder PM, Price MP, McDonald FJ et al: Mechanism by which Liddle's syndrome mutations increase activity of a human epithelial Na+ channel. Cell 1995; 83:969-78.
34. Gardner JD, Lapey A, Simopoulos P, et al: Abnormal membrane sodium transport in Liddle's syndrome. J Clin Invest 1971; 50: 2253-8.
35. Bubien JK, Lifton RP, Warnock DG: Abnormal regulation of amiloride-sensitive Na+ channels in lymphocytes from patients with Liddle's syndrome. J Am Soc Nephrol 1993; 4:508.
36. Nakada N, Koike H, Akiya T, et al: Liddle's syndrome, an uncommon form of hyporeninemic hypoaldosteronism: Functional and histopathologic studies. J Urol 1987; 137:636-40.
37. Rich GM, Ulick S, Cook S, et al: Glucocorticoid-remediable aldosteronism in a large kindred: Clinical spectrum and diagnosis using a characteristic biochemical phenotype. Ann Intern Med 1992; 116:813-20.
38. Sutherland DJ, Ruse JL, Laidlaw JC: Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. Can Med Assoc J 1966; 95:1109-19.
39. Litchfield WR, Dluhy RG, Lifton RP, et al: Glucocorticoid-remediable aldosteronism. Compr Ther 1995; 21:553-8.
40. Lifton RP, Dluhy RG, Powers M, et al: Achimaeric 11-hydroxylase/ aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 1992; 355:262-5.
41. Fallo F, Mantero F: Dexamethasone-suppressible hyperaldosteronism, in Biglieri EG, Melby JC (eds): Endocrine Hypertension. New York: Raven Press Ltd, 1990; 87-97.
42. Nadler JL, Hseuth W, Horton R: Therapeutic effect of calcium channel blockade in primary aldosteronism. Hypertension 1986; 8(suppl 1):191-4.